Patients suffering from neovascular age-related macular degeneration (nAMD) were particularly affected by these developments: as an elderly patient group, they are at higher risk for severe COVID-19 illness and should be protected from possible nosocomial transmission of the disease, on the other hand, the standard of care for active nAMD are regular anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVIs) [1]. This evidence concerns the gene VEGFA and wet macular degeneration.